Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone

Sudheer K Vuyyuru; Sarah A Morrow; Vipul Jairath

doi:10.14309/crj.0000000000000955

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone

ACG Case Rep J. 2023 Jan 20;10(1):e00955. doi: 10.14309/crj.0000000000000955. eCollection 2023 Jan.

Authors

Sudheer K Vuyyuru¹, Sarah A Morrow², Vipul Jairath¹

Affiliations

¹ Department of Medicine, Division of Gastroenterology, Schulich School of Medicine, Western University, London, Ontario, Canada.
² Department of Clinical Neurological Sciences, Schulich School of Medicine, Western University, London, Ontario, Canada.

Abstract

Simultaneous occurrence of multiple sclerosis (MS) and ulcerative colitis (UC) is seldom encountered by clinicians and poses unique challenges. The sphingosine-1-phosphate receptor modulator ozanimod has been recently approved for UC. Ozanimod can be used in such scenarios where it can treat both conditions, reducing the need for multiple targeted therapies. We report the first case of successfully treated multiple sclerosis and UC with ozanimod.

Keywords: multiple sclerosis; oral small molecules; ulcerative colitis.

Publication types

Case Reports